Latest Advances in the Treatment of Post-stroke Limb Spasm with Botulinum Neurotoxin

Source:
By:Shuhua Chen, Lingjing Jin

DOI: https://doi.org/10.30564/jams.v1i4.294

Abstract:

Objective: To describe the latest progress in the use of botulinum neurotoxin for post-stroke limb spasm. Methods: This paper looks up the relevant research literatures in recent years in PubMed, Web of Science, Springer, Ovid, CNKI, WanFang databases and summarizes them. Results: The latest progress in the use of botulinum neurotoxin for post-stroke limb spasm was studied from the following aspects: the action mechanism of botulinum neurotoxin; efficacy evaluation; injection dose; target muscle selection; guiding technology; combination therapy. Conclusion: Botulinum neurotoxin is the first-line treatment for post-stroke limb spasm. We need to make continuous improvement and progress from the treatment period, injection dose, target muscle selection, guiding technology and efficacy evaluation to improve the quality of life of the majority of post-stroke survivors in China.

References:

[1] NALYSNYK L, PAPAPETROPOULOS S, ROTELLA P, et al. OnabotulinumtoxinA muscle injection patterns in adult spasticity: a systematic literature review[J]. Bmc Neurol, 2013, 13:118. [2] SIST B, FOUAD K, WINSHIP I R. Plasticity beyond peri-infarct cortex: spinal up regulation of structural plasticity, neurotrophins, and inflammatory cytokines during recovery from cortical stroke[J]. Exp Neurol, 2014, 252:47-56. [3] PIRAZZINI M, ROSSETTO O, ELEOPRA R, et al. Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology[J]. Pharmacol Rev, 2017, 69(2):200-35. [4] GUO Y, PAN L Z, LIU W C, et al. Polyclonal neural cell adhesion molecule antibody prolongs the effective duration time of botulinum toxin in decreasing muscle strength[J]. Neurol Sci, 2015, 36(11):2019-25. [5] SERGEEVICHEV D S, KRASILNIKOVA A A, STRELNIKOV A G, et al. Globular chitosan prolongs the effective duration time and decreases the acute toxicity of botulinum neurotoxin after intramuscular injection in rats[J]. Toxicon, 2018, 143:90-5. [6] BERGFELDT U, JONSSON T, BERGFELDT L, et al. Cortical activation changes and improved motor function in stroke patients after focal spasticity therapy--an interventional study applying repeated fMRI[J]. Bmc Neurol, 2015,15:52. [7] CHANG C L, WEBER D J, MUNIN M C. Changes in Cerebellar Activation After Onabotulinumtoxin A Injections for Spasticity After Chronic Stroke: A Pilot Functional Magnetic Resonance Imaging Study[J]. Arch Phys Med Rehabil, 2015, 96(11):2007-16. [8] SMANIA N, COLOSIMO C, BENTIVOGLIO A R, et al. Use of botulinum toxin type A in the management of patients with neurological disorders: a national survey[J]. Funct Neurol, 2013, 28(4):253-8. [9] SIMPSON D M, HALLETT M, ASHMAN E J, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache Report of the Guideline Development Subcommittee of the American Academy of Neurology[J]. Neurology, 2016, 86(19): 1818-26. [10] LIM Y H, CHOI E H, LIM J Y. Comparison of Effects of Botulinum Toxin Injection Between Subacute and Chronic Stroke Patients: A Pilot Study[J]. Medicine (Baltimore), 2016, 95(7):e2851. [11] FHEODOROFF K, ASHFORD S, JACINTO J, et al. Factors influencing goal attainment in patients with post-stroke upper limb spasticity following treatment with botulinum toxin A in real-life clinical practice: sub-analyses from the Upper Limb International Spasticity (ULIS)-II Study[J]. Toxins (Basel), 2015, 7(4):1192-205. [12] DASHTIPOUR K, CHEN J J, WALKER H W, et al. Systematic literature review of abobotulinumtoxinA in clinical trials for adult upper limb spasticity[J]. Am J Phys Med Rehabil, 2015, 94(3):229-38. [13] HEIKKILA H M, JOKINEN T S, SYRJA P, et al. Assessing adverse effects of intra-articular botulinum toxin A in healthy Beagle dogs: A placebo-controlled, blinded, randomized trial[J]. Plos One, 2018, 13(1):e0191043. [14] YABLON S A, BRIN M F, VANDENBURGH A M, et al. Dose Response with OnabotulinumtoxinA for Post-Stroke Spasticity: A Pooled Data Analysis[J]. Movement Disord, 2011, 26(2):209-15. [15] WISSEL J, BENSMAIL D, FERREIRA J J, et al. Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity The TOWER study[J]. Neurology, 2017, 88(14):1321-8. [16] FRIDMAN E A, CRESPO M, GOMEZ ARGUELLO S, et al. Kinematic improvement following Botulinum Toxin-A injection in upper-limb spasticity due to stroke[J]. J Neurol Neurosurg Psychiatry, 2010, 81(4):423-7. [17] TURNER-STOKES L, FHEODOROFF K, JACINTO J, et al. Results from the Upper Limb International Spasticity Study-II (ULISII):a large, international, prospective cohort study investigating practice and goal attainment following treatment with botulinum toxin A in real-life clinical management[J]. BMJ Open, 2013, 3(6). [18] FHEODOROFF K, ASHFORD S, JACINTO J, et al. Factors influencing goal attainment in patients with post-stroke upper limb spasticity following treatment with botulinum toxin A in real-life clinical practice: sub-analyses from the Upper Limb International Spasticity (ULIS)-II Study[J]. Toxins (Basel), 2015, 7(4):1192-205. [19] RECORD OWNER N L M, INVESTIGATOR: YURA S. Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial[J]. [20] DASHTIPOUR K, CHEN J J, WALKER H W, et al. Systematic Literature Review of AbobotulinumtoxinA in Clinical Trials for Lower Limb Spasticity[J]. Medicine (Baltimore), 2016, 95(2). [21] GUPTA A D, CHU W H, HOWELL S, et al. A systematic review: efficacy of botulinum toxin in walking and quality of life in post-stroke lower limb spasticity[J]. Syst Rev, 2018, 7(1):1. [22] LI J, ZHANG R, CUI B L, et al. Therapeutic efficacy and safety of various botulinum toxin A doses and concentrations in spastic foot after stroke: a randomized controlled trial[J]. Neural Regen Res, 2017, 12(9):1451-7. [23] KIM S J, PARK H J, LEE S Y. Usefulness of strain elastography of the musculoskeletal system [J]. Ultrasonography, 2016, 35(2): 104-9. [24] WISSEL J, WARD A B, ERZTGAARD P, et al. European Consensus Table on the Use of Botulinum Toxin Type a in Adult Spasticity[J]. Journal of Rehabilitation Medicine, 2009, 41(1):13-25. [25] KLEIN A W. Contraindications and complications with the use of botulinum toxin[J]. Clin Dermatol, 2004, 22(1):66-75. [26] SANTAMATO A, PANZA F, RANIERI M, et al. Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexing proteins in the upper and lower limb spasticity after stroke[J]. J Neural Transm, 2013, 120(3):469-76. [27] NAUMANN M, BOO L M, ACKERMAN A H, et al. Immunogenicity of botulinum toxins[J]. J Neural Transm, 2013, 120(2):275-90. [28] SANTAMATO A, MICELLO M F, RANIERI M, et al. Employment of higher doses of botulinum toxin type A to reduce spasticity after stroke[J]. J Neurol Sci, 2015, 350(1-2):1-6. [29] PICELLI A, BONETTI P, FONTANA C, et al. Accuracy of botulinum toxin type A injection into the gastrocnemius muscle of adults with spastic equinus: manual needle placement and electrical stimulation guidance compared using ultrasonography [J]. Journal of Rehabilitation Medicine, 2012, 44(5):450-2. [30] CARDA S, BIASIUCCI A, MAESANI A, et al. Electrically Assisted Movement Therapy in Chronic Stroke Patients With Severe Upper Limb Paresis: A Pilot, Single-Blind, Randomized Crossover Study[J]. Arch Phys Med Rehabil, 2017, 98(8): 1628-35 e2. [31] NAKIPOGLU YUZER G F, KOSE DONMEZ B, OZGIRGIN N. A Randomized Controlled Study: Effectiveness of Functional Electrical Stimulation on Wrist and Finger Flexor Spasticity in Hemiplegia[J]. J Stroke Cerebrovasc Dis, 2017, 26(7): 1467-71. [32] JUNG K S, IN T S, CHO H Y. Effects of sit-to-stand training combined with transcutaneous electrical stimulation on spasticity, muscle strength and balance ability in patients with stroke: A randomized controlled study[J]. Gait Posture, 2017, 54:183-7. [33] KREWER C, HARTL S, MULLER F, et al. Effects of repetitive peripheral magnetic stimulation on upper-limb spasticity and impairment in patients with spastic hemiparesis: a randomized, double-blind, sham-controlled study[J]. Arch Phys Med Rehabil, 2014, 95(6):1039-47. [34] SANTAMATO A, MICELLO M F, PANZA F, et al. Extracorporeal shock wave therapy for the treatment of poststroke plantar-flexor muscles spasticity: a prospective open-label study[J]. Top Stroke Rehabil, 2014, 21 Suppl 1, S17-24. [35] VLAAR M P, SOLIS-ESCALANTE T, DEWALD J P A, et al. Quantification of task-dependent cortical activation evoked by robotic continuous wrist joint manipulation in chronic hemiparetic stroke[J]. J Neuroeng Rehabil, 2017, 14(1):30. [36] JIANG L, DOU Z L, WANG Q, et al. Evaluation of clinical outcomes of patients with post-stroke wrist and finger spasticity after ultrasonography-guided BTX-A injection and rehabilitation training[J]. Front Hum Neurosci, 2015, 9:485. [37] SANTAMATO A, MICELLO M F, PANZA F, et al. Adhesive taping vs. daily manual muscle stretching and splinting after botulinum toxin type A injection for wrist and fingers spastic overactivity in stroke patients: a randomized controlled trial[J]. Clin Rehabil, 2015, 29(1):50-8. [38] HURD C, LIVINGSTONE D, BRUNTON K, et al. Early Intensive Leg Training to Enhance Walking in Children with Perinatal Stroke: Protocol for a Randomized Controlled Trial[J]. Phys Ther, 2017, 97(8):818-25. [39] ZOROWITZ R D, WEIN T H, DUNNING K, et al. A Screening Tool to Identify Spasticity in Need of Treatment[J]. Am J Phys Med Rehabil, 2017, 96(5):315-20. [40] LI S. Spasticity, Motor Recovery, and Neural Plasticity after Stroke[J]. Front Neurol, 2017, 8:120. [41] CHEUNG J, RANCOURT A, DI POCE S, et al. Patient-Identified Factors That Influence Spasticity in People with Stroke and Multiple Sclerosis Receiving Botulinum Toxin Injection Treatments[J]. Physiother Can, 2015, 67(2):157-66. [42] BENSMAIL D, HANSCHMANN A. Satisfaction with botulinum toxin treatment in post-stroke spasticity: Results from two cross-sectional surveys of patients and physicians[J]. Movement Disord, 2014, 29:S404-S. [43] BARNES M P, BEST D, KIDD L, et al. The use of botulinum toxin type-B in the treatment of patients who have become unresponsive to botulinum toxin type-A- initial experiences[J]. Eur J Neurol, 2005, 12(12):947-55.